Kunihiko Kobayashi - Concepedia

Author

Kunihiko Kobayashi

Also Known As

K KOBAYASHI, K Kobayashi, K Komiyama, K. KOBAYASHI, K. Kobayashi, KUNIHIKO KOBAYASHI, Keiko KOBAYASHI, Kobayashi K, Kobayashi Kunihiko, Kunihiko KOBAYASHI

859

Publications

23.7K

Citations

H-Index

362

Concepts

All Affiliations

Hokkaido University Saitama Medical University Nippon Medical School Yamaguchi University Kyoto University

About

Kunihiko Kobayashi is an author at Hokkaido University specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	47	159	9.1K
2	Health Sciences	18	27	1.8K
3	Engineering	16	24	847
4	Education	8	8	189
5	Management	1	1	53

Kunihiko Kobayashi

309

Publications

21.9K

Citations

H-Index

Page 1

	Year	Citations
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, New England Journal of Medicine	2010	5.5K
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial Haruhiro Saito, Tatsuro Fukuhara, Naoki Furuya, The Lancet Oncology Interim AnalysisOncologyBevacizumab Versus ErlotinibPathologyImmune Checkpoint Inhibitor	2019	626
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2018	568
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Annals of Oncology OncologyPathologyCancer TreatmentCancer GeneticsMedicine	2012	549
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC David Planchard, Pasi A. Jänne, Ying Cheng, New England Journal of Medicine	2023	546
Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp Yoshiaki Nagai, Hitoshi Miyazawa, Huqun, Cancer Research PathologySensitive Detection SystemNucleic Acid BiomarkersTumor BiologyTumor Heterogeneity	2005	506
Screening for estrogen and androgen receptor activities in 200 pesticides by in vitro reporter gene assays using Chinese hamster ovary cells. Hiroyuki Kojima, Eiji Katsura, Shinji Takeuchi, Environmental Health Perspectives Pesticide-residue AnalysisGeneticsGynecologyReproductive BiologyHuman Estrogen Receptor	2003	502
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study Yukio Hosomi, Satoshi Morita, Shunichi Sugawara, Journal of Clinical Oncology	2019	473
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy Hiroshi Kagamu, Shigehisa Kitano, Ou Yamaguchi, Cancer Immunology Research Anti-pd-1 TherapyPd-1 BlockadeT-regulatory CellImmunologyImmune Regulation	2019	255
A cross-validation of the European organization for research and treatment of cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with Lung Cancer Kunihiko Kobayashi, Fumikazu Takeda, Satoshi Teramukai, European Journal of Cancer OncologyCancer Qlq-c30PathologyBronchial NeoplasmEuropean Organization	1998	253

Page 1